Evotec, UCB in Multi-Target Collaboration

Evotec AG has entered into a multi-target drug discovery collaboration with UCB in the field of immunology. Evotec will apply its drug discovery expertise to identify small molecules against a selected number of targets, then optimize a preclinical candidate. Evotec will receive research funding and will receive early stage discovery, preclinical and clinical milestones, as well as royalties on sales of any approved drugs from the collaboration. Financial details were not disclosed.
 
Dr. Werner Lanthaler, chief executive officer of Evotec, said, “We are extremely pleased that UCB has again selected Evotec to collaborate on this second significant Drug Discovery Collaboration. This integrated drug discovery deal showcases our broad target class expertise coupled with our industry-leading platform. We look forward to a fruitful collaboration with our scientific colleagues and friends at UCB.”